Published in Pharma Law Weekly, July 26th, 2005
According to recent research from Australia, "The p14(ARF) tumor suppressor regulates a series of cell cycle regulatory proteins to promote cell cycle arrest in response to abnormal hyperproliferative growth stimuli. p14(ARF) alterations are common in human cancers and, when inherited, confer susceptibility to cutaneous melanoma. We now propose that the mechanism of p14(ARF) action may involve the covalent modification of its binding partners with the small ubiquitin-related protein SUMO-1."
"In particular, we...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly